As of 2024-12-15, the EV/EBITDA ratio of Alpine Immune Sciences Inc (ALPN) is -87.88. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. ALPN's latest enterprise value is 4,423.93 mil USD. ALPN's TTM EBITDA according to its financial statements is -50.34 mil USD. Dividing these 2 quantities gives us the above ALPN EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.6x - 16.8x | 15.9x |
| Forward P/E multiples | 15.2x - 21.1x | 15.5x |
| Fair Price | (10.67) - (11.85) | (11.04) |
| Upside | -116.4% - -118.2% | -117.0% |
| Date | EV/EBITDA |